Biogen prices new MS drug at discount to key competitors

WASHINGTON (Reuters) - Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/0FpXic0oHDw/story01.htm

phlebotomy training milwaukee phlebotomy certification classes government funded training courses